Abstracts tagged "pain and steroids"

Abstract Number: 2668 • 2013 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, An Intra-Articular (IA) Sustained-Release Formulation Of Triamcinolone Acetonide (TCA), To An Approved Injectable Suspension Of TCA In Patients With Osteoarthritis (OA) Of The Knee
Neil Bodick¹, Joelle Lufkin¹, Christina Willwerth¹, Pierre Lachance², Gregory Jasey³, Anil Gupta⁴, Anthony Chris⁵, Marc Russo⁶, Michael O'Mahony⁷, Sam Henein⁸, Louise Murdoch⁹, Ferdinandus de Looze¹⁰, David Hunter¹¹ and Michael Clayman¹, ¹Flexion Therapeutics, Burlington, MA, ²Clinique St-Louis (Recherche) Inc, Quebec, QC, Canada, ³North Walkerville Orthopaedic Associates, Windsor, ON, Canada, ⁴Anil K. Gupta Medicine Professional Corporation, Toronto, ON, Canada, ⁵Aim Health Group, Waterloo, ON, Canada, ⁶Hunter Clinical Research, Broadmeadow, Australia, ⁷London Road Diagnostic Clinic and Medical Centre, Sarnia, ON, Canada, ⁸SKDS Research Inc., Newmarket, ON, Canada, ⁹Emeritus Research, Malvern East, Australia, ¹⁰AusTrials Pty Limited, Sherwood, Australia, ¹¹Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: FX006 is a novel sustained-release formulation of TCA in poly(lactic-co-glycolic) acid microspheres intended to maintain therapeutic concentrations in the joint up to 3 months…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].